Roger Jeffs Sells 6,428 Shares of Liquidia (NASDAQ:LQDA) Stock

Posted by Brenda Bartman on May 28th, 2026

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) CEO Roger Jeffs sold 6,428 shares of the company’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $62.18, for a total value of $399,693.04. Following the completion of the sale, the chief executive officer owned 1,041,667 shares of the company’s stock, valued at $64,770,854.06. This represents a 0.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roger Jeffs also recently made the following trade(s):

On Tuesday, May 26th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $60.38, for a total value of $1,509,500.00.
On Thursday, May 21st, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $61.13, for a total value of $1,528,250.00.
On Tuesday, May 19th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $58.65, for a total value of $1,466,250.00.
On Friday, May 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $57.04, for a total value of $1,426,000.00.
On Wednesday, May 13th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $56.29, for a total value of $1,407,250.00.
On Monday, May 11th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $41.50, for a total value of $1,037,500.00.
On Thursday, May 7th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $42.09, for a total value of $1,052,250.00.
On Tuesday, May 5th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.10, for a total value of $1,002,500.00.
On Friday, April 17th, Roger Jeffs sold 18,839 shares of Liquidia stock. The stock was sold at an average price of $40.60, for a total value of $764,863.40.
On Wednesday, April 15th, Roger Jeffs sold 25,000 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total value of $1,003,500.00.

Liquidia Price Performance

Shares of NASDAQ LQDA remained flat at $62.03 during mid-day trading on Thursday. The company had a trading volume of 837,919 shares, compared to its average volume of 1,684,329. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. The firm has a market capitalization of $5.52 billion, a PE ratio of 443.10 and a beta of 0.41. Liquidia Corporation has a 1 year low of $11.85 and a 1 year high of $63.46. The business has a 50-day simple moving average of $43.52 and a 200-day simple moving average of $38.05.

Liquidia (NASDAQ:LQDA – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.Liquidia’s revenue for the quarter was up 4187.1% compared to the same quarter last year. On average, equities analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on LQDA. Needham & Company LLC upped their price objective on Liquidia from $54.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. BTIG Research increased their price target on Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Oppenheimer increased their price target on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research note on Thursday, March 12th. Finally, HC Wainwright increased their price target on Liquidia from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Three analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $50.88.

View Our Latest Research Report on Liquidia

Institutional Investors Weigh In On Liquidia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. purchased a new stake in Liquidia in the fourth quarter valued at about $25,000. Covestor Ltd increased its holdings in shares of Liquidia by 41.9% in the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock valued at $42,000 after purchasing an additional 359 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new position in shares of Liquidia in the third quarter valued at about $30,000. FNY Investment Advisers LLC acquired a new position in shares of Liquidia in the third quarter valued at about $34,000. Finally, NewEdge Advisors LLC acquired a new position in shares of Liquidia in the second quarter valued at about $25,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

About Liquidia

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).